Skip to main content
. 2015 Nov;3(19):279. doi: 10.3978/j.issn.2305-5839.2015.11.21

Figure 3.

Figure 3

Clinical pathway of sorafenib treatment. d, in patients with a RECIST assessment of “PD”, the treatment may be selected after the efficacy is confirmed by the researcher (e.g., combined with Choi assessment); g, please refer to the information described in the main text concerning the third-line treatment; h, dosage should be adjusted according to toxicity grade, and the minimal dose should not be lower than sorafenib 200 mg qd. TKI, tyrosine kinase inhibitor.